Related Experiment Video
Updated: Jun 8, 2026

Detection and Visualization of DNA Damage-induced Protein Complexes in Suspension Cell Cultures Using the Proximity Ligation Assay
Published on: June 9, 2017
ATM kinase activity modulates cFLIP protein levels: potential interplay between DNA damage signalling and
Venturina Stagni1, Michele Mingardi, Simonetta Santini
1Laboratory of Cell Signaling, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Fondazione Santa Lucia, Rome, Italy.
Abstract:
Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) has been proposed as a potent tool to trigger apoptosis in cancer therapy. However, since ∼60% of tumour cell lines and most primary cancers are resistant to TRAIL-induced apoptosis, several combined therapy approaches aimed to sensitize cells to TRAIL have been developed. One of the major targets of these approaches are cFLIP proteins as they interfere with the initiation of apoptosis induction by TRAIL, are over-expressed in many cancers and their down-regulation enhances TRAIL sensitivity. Although, DNA-damaging agents such as 5-fluorouracil (5-FU), etoposide and adriamycin have been successfully employed due to their ability to trigger cFLIP(L) and cFLIP(s) down-regulation the molecular mechanisms underneath their action have been only partially elucidated. We have recently identified ataxia telangiectasia mutated (ATM) as a modulator of cFLIP(L) and cFLIP(S) protein levels in the DNA damage response. Here, we provide genetic evidence that ATM kinase activity is required to trigger 5-FU- and neocarzinostatin-dependent cFLIP(L) and cFLIP(S) down-regulation, which in turn sensitize hepatocellular carcinoma (HCC) cell lines to TRAIL. ATM activity triggers cFLIP proteins down-regulation in HCC cells independently on p53 and enhances cFLIP(L) ubiquitination in response to DNA damage. Therefore, we propose that ATM kinase mediates the interplay between DNA damage and death receptor signalling and suggest that expression of catalytically competent ATM in tumour cells may play a key role for successful combinatorial use of TRAIL receptor agonists and DNA-damaging drugs in cancer therapy.
Insights
Ataxia telangiectasia mutated (ATM) kinase activity is crucial for down-regulating cFLIP proteins following DNA damage, enhancing cancer cells
Area of Science:
- Molecular Biology
- Cancer Therapy
- Cell Death Signaling
Background:
- Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) shows promise for cancer therapy, but many cancers exhibit resistance.
- cFLIP proteins inhibit TRAIL-induced apoptosis and are often overexpressed in cancers, making them a target for sensitization strategies.
- DNA-damaging agents like 5-fluorouracil (5-FU) can down-regulate cFLIP, but the underlying mechanisms are not fully understood.
Purpose of the Study:
- To investigate the role of Ataxia Telangiectasia Mutated (ATM) kinase in the down-regulation of cFLIP proteins upon DNA damage.
- To determine if ATM activity is required for DNA-damaging agents to sensitize hepatocellular carcinoma (HCC) cells to TRAIL.
- To elucidate the molecular mechanisms by which ATM influences cFLIP levels and TRAIL sensitivity.
Main Methods:
- Genetic evidence was used to assess the requirement of ATM kinase activity.
- Hepatocellular carcinoma (HCC) cell lines were treated with DNA-damaging agents (5-FU, neocarzinostatin).
- cFLIP protein levels, ubiquitination, and sensitivity to TRAIL were analyzed in response to DNA damage and ATM activity.
Main Results:
- ATM kinase activity is essential for the down-regulation of both cFLIP(L) and cFLIP(S) isoforms induced by 5-FU and neocarzinostatin.
- ATM-mediated cFLIP down-regulation sensitizes HCC cell lines to TRAIL-induced apoptosis.
- ATM enhances cFLIP(L) ubiquitination in response to DNA damage, independent of p53.
Conclusions:
- ATM kinase acts as a critical mediator linking DNA damage response pathways with death receptor signaling.
- ATM activity is required for sensitizing cancer cells to TRAIL via DNA-damaging agents.
- The expression of functional ATM in tumor cells may be vital for the success of combined TRAIL-based and DNA-damaging therapies.
Related Concept Videos
DNA Damage can Stall the Cell Cycle
DNA Damage Can Stall the Cell Cycle
The Intrinsic Apoptotic Pathway
The Extrinsic Apoptotic Pathway
PI3K/mTOR/AKT Signaling Pathway
MAPK Signaling Cascades

